摘要
目的探究胃癌相关性贫血使用促红素进行治疗临床疗效以及预后情况。方法选取我院2015年4月~2016年8月收入98例胃癌相关性贫血患者作为此次研究对象,按照治疗方式不同分为观察组和对照组,各49例,对照组使用常规化疗以及常规抗贫血治疗,观察组使用常规化疗并予以促红素治疗,比较两组血液水平指标变化、临床治疗效以及不良反应发生率。结果两组治疗前后血液指标水平变化中两组治疗前差异无统计学意义(P>0.05),两组治疗后差异有统计学意义(P<0.05),两组治疗疗效比较中观察组95.9%高于对照组79.6%,差异有统计学意义(P<0.05),两组不良反应中观察组14.3%低于对照组30.6%,两组差异有统计学意义(P<0.05)。结论临床上使用促红素对于肿瘤相关性贫血治疗效果较为明显,可以使血红蛋白有效升高,减少临床上不良反应发生,可以在临床上推广使用。
Objective To investigate the clinical curative effect and prognosis of patients with gastric cancerrelated anemia. Methods In this study,98 patients with gastric cancer associated anemia in our hospital were divided into observation group（n=49） and control group（n=49）.The patients in the control group were treated with conventional chemotherapy and antianemia therapy,while the patients in the observation group were treated with conventional chemotherapy and propofol.The changes of blood level,the clinical curative effect and the incidence of adverse reactions were compared between the two groups. Results There was no significant difference before and after treatment between the two groups（P〉0.05）.The difference between the two groups after treatment was statistically significant（P〈0.05）.The observation group was 95.9% higher than the control group（79.6%） in the comparison of therapeutic efficacy.The difference was statistically significant.The adverse reactions in the observation group were lower than that in the control group（14.3% vs 30.6%,P〈0.05）,and the difference between the two groups was statistically significant（P〈0.05）. Conclusion The clinical effect of the treatment of tumor-associated anemia by using propofol is obvious,which can effectively increase hemoglobin,reduce the occurrence of clinical adverse reactions,and can be popularized in clinic.
作者
刘希
张吉发
LIU Xi;ZHANG Jifa(Department of Oncology and Hematology,Panzhihua Central Hospital,Panzhihua 617000,China)
出处
《中国医药科学》
2018年第9期240-242,共3页
China Medicine And Pharmacy
关键词
促红素
相关性贫血
预后
影响观察
Erythropoietin
Related anemia
Prognosis
Influence observation
